[CAS NO. 376348-65-1] Maraviroc

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [376348-65-1]

Catalog

HY-13004

Brand

MCE

CAS

376348-65-1

DESCRIPTION [376348-65-1]

Overview

MDL	MFCD13188530
Molecular Weight	513.67
Molecular Formula	C29H41F2N5O
SMILES	O=C(C1CCC(F)(F)CC1)N[C@H](C2=CC=CC=C2)CCN3[C@H]4C[C@@H](N5C(C)=NN=C5C(C)C)C[C@@H]3CC4

For research use only. We do not sell to patients.

18 Publications Citing Use of MCE

Summary

Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV .

IC50 & Target

MIP-1α-CCR5

3.3 nM (IC ₅₀ , in HEK-293 cell membrane)

RANTES-CCR5

5.2 nM (IC ₅₀ , in HEK-293 cell membrane)

MIP-1β-CCR5

7.2 nM (IC ₅₀ , in HEK-293 cell membrane)

HIV-1 (Ba-L)

1.1 nM (IC ₅₀ , in PM-1 cells)

In Vitro

Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity. Maraviroc inhibits the downstream event of chemokine-induced intracellular calcium redistribution, with IC ₅₀ s ranging from 7 to 30 nM obtained against MIP-1β, MIP-1α and RANTES.
Maraviroc (UK-427857) is active (IC ₉₀ ) at low nanomolar concentrations against HIV-1 Ba-L (a lab-adapted R5 strain) when measured in a 5-day antiviral assay using either isolated multiple (pooled) donor PBMC (IC ₉₀ , 3.1 nM), single-donor PBMC (IC ₉₀ , 1.8 nM) or PM-1 cells (IC ₉₀ , 1.1 nM) ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Clearance values are moderate to high in both rat and dog species following i.v. administration (74 and 21 mL/min/kg, respectively). Maraviroc also has a moderate volume of distribution in both species (4.3 to 6.5 liters/kg). The half-life values of maraviroc are 0.9 h in the rat and 2.3 h in the dog. Following oral administration (2 mg/kg) to the dog, the C _max (256 ng/mL) occurs 1.5 h. post-dose, and the bioavailability is 40%. For the rat, investigation of the concentrations obtain in the portal vein following oral administration indicated that approximately 30% of the administered dose is absorbed from the intestinal tract ^[1] . In the DSS/TNBS colitis and in the transfer model, Maraviroc attenuates development of intestinal inflammation by selectively reducing the recruitment of CCR5 bearing leukocytes ^[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00098306	ViiV Healthcare\|Pfizer	HIV Infections	November 2004	Phase 2\|Phase 3
NCT04435522	Rhode Island Hospital	COVID	October 1, 2020	Phase 1
NCT02519777	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections	April 21, 2016	Phase 4
NCT01894776	Ottawa Hospital Research Institute\|Pfizer	HIV Infection\|HIV-1 Infection\|Mycobacterium Avium Complex (MAC)	June 2013	Phase 1
NCT01736813	National Center for Tumor Diseases, Heidelberg\|University Hospital Heidelberg	Colorectal Cancer\|Neoplasm Metastasis\|Liver Metastases	November 2012
NCT01140412	ViiV Healthcare\|Pfizer	Healthy	July 2010	Phase 1
NCT00944541	French National Agency for Research on AIDS and Viral Hepatitis\|Pfizer	HIV Infection\|HIV Infections	September 2009	Phase 2
NCT01384682	Kirby Institute\|ViiV Healthcare\|Pfizer	HIV	August 2011	Phase 4
NCT03274804	University Hospital Heidelberg\|Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest	Metastatic Colorectal Cancer\|MSS	April 1, 2018	Phase 1
NCT02208037	National Heart, Lung, and Blood Institute (NHLBI)\|Blood and Marrow Transplant Clinical Trials Network\|National Cancer Institute (NCI)	Acute Leukemia\|Chronic Myelogenous Leukemia\|Myelodysplasia\|Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|Lymphoma, B-Cell\|Lymphoma, Follicular\|Lymphoma, Large B-Cell, Diffuse\|Hodgkin´s Lymphoma	August 2014	Phase 2
NCT00719823	ViiV Healthcare\|Pfizer	Human Immunodeficiency Virus Type 1	August 2008	Phase 3
NCT02741323	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Kidney Diseases	January 1, 2017	Phase 2
NCT02486510	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	HIV-1 Infection	July 2012	Early Phase 1
NCT02167451	Children´s Hospital Medical Center, Cincinnati	Diagnoses That Require Stem Cell Transplant\|Graft Versus Host Disease (GVHD)	July 2014	Phase 1\|Phase 2
NCT04789616	University of Calgary\|University Health Network, Toronto\|University of California, Los Angeles\|Sunnybrook Health Sciences Centre\|University of British Columbia\|Memorial University of Newfoundland\|Dalhousie University\|Parkwood Hospital, London, Ontario\|Riverview Health Centre Foundation\|The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	Stroke	May 2022	Phase 2
NCT00981773	Imperial College London\|Mater Misericordiae University Hospital	HIV Infections	September 2009	Phase 4
NCT00948753	Abramson Cancer Center of the University of Pennsylvania	Graft-versus-host Disease\|Hematopoietic Stem Cell Transplantation	June 2009	Phase 1\|Phase 2
NCT03172026	University of California, Los Angeles	Stroke	August 1, 2019	Phase 2\|Phase 3
NCT05470491	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	HIV\|Hematologic Malignancies	November 27, 2022	Phase 1\|Phase 2
NCT00870363	University of California, Davis	HIV Infections	April 2009	Phase 4
NCT00808002	Germans Trias i Pujol Hospital	HIV Infections	February 2009	Phase 3
NCT04965662	Guy´s and St Thomas´ NHS Foundation Trust\|ViiV Healthcare\|Gilead Sciences	HIV-1-infection	January 1, 2018	Phase 4
NCT02475915	South East Asia Research Collaboration with Hawaii\|The Thai Red Cross AIDS Research Centre\|Cooper Human Systems	Acute HIV Infection	January 2015	Phase 1\|Phase 2
NCT01585753	Kirby Institute	Cardiovascular Disease	June 2012
NCT00098748	ViiV Healthcare\|Pfizer	HIV Infections	November 2004	Phase 2\|Phase 3
NCT00977756	International Maternal Pediatric Adolescent AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections	August 2002
NCT02990312	University of Maryland, Baltimore	Hiv\|Kidney Transplant\|HIV Reservoir\|CCR5	May 1, 2017	Phase 4
NCT00795444	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal\|Pfizer	HIV-1	March 2008	Phase 2
NCT00844519	University of California, San Francisco\|National Heart, Lung, and Blood Institute (NHLBI)\|Pfizer	HIV Infection\|Cardiovascular Disease\|Inflammation\|HIV Infections	January 2010	Phase 3
NCT02346084	International Partnership for Microbicides, Inc.\|National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health (NIH)	HIV+AIDS	January 2015	Phase 1
NCT03163277	Giovanni Di Perri\|University of Turin, Italy	Hiv\|Neurocognitive Dysfunction	May 15, 2017	Phase 4
NCT01980329	Johns Hopkins University	Cytochrome P450 CYP3A5 Enzyme Polymorphism\|Healthy Subjects\|Pharmacokinetics of Maraviroc	January 2013	Phase 1
NCT04475991	Hospital General de México Dr. Eduardo Liceaga\|CCINSHAE. Secretaría de Salud. México\|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran\|Centro de Investigación en. Enfermedades Infecciosas, Mexico	COVID-19	July 13, 2021	Phase 2
NCT00827112	ViiV Healthcare\|Pfizer	Human Immunodeficiency Virus-1	March 2009	Phase 2
NCT00042289	National Institute of Allergy and Infectious Diseases (NIAID)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	HIV Infections	June 9, 2003
NCT01204905	University of Maryland, Baltimore\|Merck Sharp & Dohme LLC	HIV Infections	September 2010	Not Applicable
NCT01068873	Temple University\|Abbott\|Pfizer	HIV Infections	April 2010	Phase 4
NCT02934022	Southern California Institute for Research and Education\|Pfizer	HIV Infection	June 2012	Not Applicable
NCT01680536	St Stephens Aids Trust	HIV	November 2012	Phase 4
NCT00771823	St Stephens Aids Trust	HIV Infections	May 2008	Phase 1
NCT00982878	Imperial College London\|Pfizer	HIV Infections	September 2009	Phase 1
NCT02961829	Federal University of São Paulo\|Fundação de Amparo à Pesquisa do Estado de São Paulo\|Conselho Nacional de Desenvolvimento Científico e Tecnológico\|ViiV Healthcare	Chronic Infection\|HIV	July 2015	Not Applicable
NCT01154673	University of Toronto\|Unity Health Toronto\|Maple Leaf Research	Acute HIV Infection	November 2011	Phase 2\|Phase 3
NCT00966329	Germans Trias i Pujol Hospital	HIV\|HIV Infections	October 2009	Phase 4
NCT00426660	ViiV Healthcare	HIV Infections	February 2007	Phase 3
NCT01329783	ViiV Healthcare\|Copenhagen HIV Programme\|Pfizer	HIV\|AIDS	April 2007
NCT01363037	International Partnership for Microbicides, Inc.	HIV Infections	November 2011	Phase 1
NCT01627717	Centre hospitalier de l´Université de Montréal (CHUM)\|Université de Montréal\|McGill University Health Centre+Research Institute of the McGill University Health Centre\|Toronto General Hospital	Healthy	June 2012	Phase 1
NCT00709111	AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections	January 2009	Not Applicable
NCT01597648	GlaxoSmithKline	Infection, Human Immunodeficiency Virus I	November 2011	Phase 1
NCT04710199	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Virus Diseases	February 23, 2021	Phase 2
NCT00976404	Robert L. Murphy\|Objectif Recherche Vaccins SIDA\|National Institute of Allergy and Infectious Diseases (NIAID)\|Pfizer\|Merck Sharp & Dohme LLC\|Northwestern University	HIV Infection	November 2009	Phase 2
NCT01133210	Washington University School of Medicine\|Pfizer	Hypertriglyceridemia	January 2011	Phase 1
NCT00791700	ViiV Healthcare\|Pfizer	Human Immunodeficiency Virus	April 22, 2009	Phase 2
NCT04721301	University Hospital Heidelberg\|German Cancer Research Center	Colorectal Cancer Metastatic\|Pancreatic Cancer Metastatic	January 15, 2017	Phase 1
NCT01276236	University of California, San Francisco\|Pfizer\|ViiV Healthcare	Kaposi´s Sarcoma	March 9, 2011	Phase 2
NCT00981318	Rodwick, Barry M., M.D.\|Abbott	HIV Infections\|Acquired Immunodeficiency Syndrome	December 2009	Phase 4
NCT01597895	ViiV Healthcare\|Pfizer	Healthy	July 2012	Phase 1
NCT00884858	ASST Fatebenefratelli Sacco	HIV Infections	April 2009	Phase 4
NCT03129113	University College, London\|Medical Research Council\|ViiV Healthcare\|Royal Free Hospital NHS Foundation Trust	Hepatic Steatosis\|HIV-1-infection	March 1, 2017	Phase 2\|Phase 3
NCT01348308	ANRS, Emerging Infectious Diseases\|Pfizer	HIV-1 Infection\|AIDS	September 2011	Phase 3
NCT01013987	Fundación Huésped\|Pfizer	HIV-1 Adults Patients\|AIDS\|Triple Class Failure	February 2010	Phase 4
NCT00801515	ViiV Healthcare\|Pfizer	HIV	August 2009
NCT00925756	University of California, San Diego\|University of California, Los Angeles\|University of Southern California\|Pfizer\|California HIV+AIDS Research Program	HIV Infections	October 20, 2008	Phase 4
NCT01389063	S.F.L. van Lelyveld\|UMC Utrecht	Endothelial Dysfunction	January 2012	Phase 4
NCT01242579	International Partnership for Microbicides, Inc.	HIV Infections	January 2011	Phase 1
NCT00735072	University of California, San Francisco\|Pfizer\|amfAR, The Foundation for AIDS Research\|Stanford University\|Case Western Reserve University\|Rush University	HIV Infection	September 2008	Phase 4
NCT02480894	ViiV Healthcare\|GlaxoSmithKline	Infection, Human Immunodeficiency Virus	July 7, 2015	Phase 1
NCT00992654	ViiV Healthcare\|Pfizer	Human Immunodeficiency Virus (HIV)
NCT00783484	Pfizer	Healthy Volunteers	October 2008	Phase 1
NCT01190293	St Stephens Aids Trust	HIV Infection	January 2010	Phase 4
NCT02134717	Kevin F. Gibson\|University of Pittsburgh	Sarcoidosis	January 2014	Not Applicable
NCT02625207	ViiV Healthcare\|Pfizer	Healthy Subjects	November 6, 2015	Phase 1
NCT00643643	ViiV Healthcare\|Pfizer	HIV Infections	October 2002	Phase 2
NCT01505114	National Institute of Allergy and Infectious Diseases (NIAID)\|HIV Prevention Trials Network\|AIDS Clinical Trials Group	HIV Infection	June 2012	Phase 2
NCT01637233	Kirby Institute	HIV-1 Infection	June 2012
NCT01533272	Hospital Clinic of Barcelona	HIV Infection	February 2012	Phase 4
NCT01785810	Abramson Cancer Center of the University of Pennsylvania	Hematologic Malignancy	February 2013	Phase 2
NCT01049204	St Stephens Aids Trust	HIV Infections	July 2009	Phase 4
NCT00665561	ViiV Healthcare\|Pfizer	Human Immunodeficiency Virus	March 31, 2008
NCT00853840	ViiV Healthcare\|Pfizer	AIDS	April 2008	Phase 4
NCT03178084	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	HIV+AIDS	October 15, 2014	Phase 3
NCT04966429	Tel-Aviv Sourasky Medical Center\|Hadassah Medical Organization\|Soroka University Medical Center	Post Stroke Cognitive Impairment	May 1, 2021	Phase 2
NCT02039323	University of North Carolina, Chapel Hill	Healthy Adult Females	February 2014	Phase 1
NCT03402815	University Of Perugia	HIV Infection With Other Conditions\|Cardiovascular Risk Factor\|Atherosclerosis\|Inflammation	January 1, 2015	Phase 4
NCT01327547	ViiV Healthcare\|Pfizer	HIV Coinfection	May 18, 2011	Phase 4
NCT00782301	ViiV Healthcare\|Pfizer	Hepatitis B\|Human Immunodeficiency Virus\|Hepatitis C, Chronic	March 2009	Phase 4
NCT00537394	National Institute of Allergy and Infectious Diseases (NIAID)\|AIDS Clinical Trials Group	HIV Infections	January 2008	Phase 3
NCT00634959	ViiV Healthcare\|Pfizer	HIV	July 2003	Phase 2
NCT00666705	ViiV Healthcare\|Pfizer	Healthy	February 2008	Phase 4
NCT01896921	University of Maryland, Baltimore	HIV	September 2013	Phase 3
NCT00496782	ViiV Healthcare\|Pfizer	HIV Infections	July 2007	Phase 1
NCT03708861	University of Turin, Italy	HIV Infection	January 2016	Phase 3
NCT00988780	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran\|University of Witwatersrand, South Africa\|Case Western Reserve University\|The Wistar Institute\|University of Pennsylvania	Immune Reconstitution Inflammatory Syndrome\|HIV\|HIV Infections	December 2009	Not Applicable
NCT01866267	St. Hope Foundation\|GlaxoSmithKline	Human Immunodeficiency Virus\|AIDS	January 2013	Phase 4
NCT03218592	University of North Carolina, Chapel Hill\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV+AIDS	June 28, 2017	Phase 4
NCT00098722	ViiV Healthcare\|Pfizer	HIV Infections	December 2004	Phase 2\|Phase 3
NCT01749566	Emory University	HIV	December 2012	Phase 1
NCT02881762	University of Maryland, Baltimore\|ViiV Healthcare	Hepatitis C\|Human Immunodeficiency Virus	June 1, 2017	Phase 4
NCT01235013	Hospital Clinic of Barcelona	HIV-1 Infection		Phase 4
NCT01637259	Kirby Institute	Proteinuria\|HIV	June 2012	Phase 4
NCT02333045	Emory University	HIV	January 2015	Not Applicable
NCT01348763	Imperial College London	HIV	October 2011	Phase 1
NCT00987948	University of Hawaii\|Pfizer	HIV Infections	January 2010	Phase 2
NCT01290211	ViiV Healthcare\|Pfizer	Healthy	April 2011	Phase 1
NCT04441385	Hospital Universitario Infanta Leonor\|Hospital Clinic of Barcelona\|ViiV Healthcare	COVID-19	June 26, 2020	Phase 2
NCT00717067	ViiV Healthcare\|Pfizer	Human Immunodeficiency Virus (HIV) Infection	July 2008	Phase 4
NCT01449006	Bruce Brew\|ViiV Healthcare\|St Vincent´s Hospital, Sydney	Human Immunodeficiency Virus (HIV)\|HIV Associated Neurocognitive Disorders (HAND)	October 2011	Phase 4
NCT01060618	Asociacion para el Estudio de las Enfermedades Infecciosas	HIV Infections	May 2009	Phase 2\|Phase 3
NCT02159027	University of Hawaii\|ViiV Healthcare\|University of Puerto Rico	AIDS Dementia Complex	June 2015	Phase 2\|Phase 3
NCT02799888	Affiliated Hospital to Academy of Military Medical Sciences	Graft-versus-host Disease\|Hematopoietic Stem Cell Transplantation	April 2014	Phase 2
NCT00098293	ViiV Healthcare\|Pfizer	HIV-1	November 2004	Phase 3
NCT00875368	S.F.L. van Lelyveld\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Erasmus Medical Center\|Leiden University Medical Center\|Onze Lieve Vrouwe Gasthuis\|Slotervaart Hospital\|Rijnstate Hospital\|Pfizer\|UMC Utrecht	HIV Infections	February 2009	Phase 4
NCT01400412	AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV-1 Infection	January 17, 2012	Phase 2
NCT00775294	University of North Carolina, Chapel Hill\|Pfizer	HIV+AIDS	May 2008	Phase 1
NCT01719627	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	HIV	October 2012	Phase 1
NCT01345630	ViiV Healthcare\|Pfizer	HIV-1	September 2011	Phase 3
NCT00821535	ViiV Healthcare\|Pfizer	Human Immunodeficiency Virus (HIV) Infection	February 2009	Phase 1
NCT00427934	Pfizer	Arthritis, Rheumatoid	February 2007	Phase 2
NCT01428986	National Center for Global Health and Medicine, Japan	HIV Infections\|AIDS	November 2009
NCT00850395	ViiV Healthcare\|Pfizer	HIV-1	July 2009
NCT00764465	Garden State Infectious Disease Associates, PA\|GlaxoSmithKline	Healthy	October 2008	Phase 2
NCT00703586	Rockefeller University\|Aaron Diamond AIDS Research Center\|Pfizer	HIV Infections	September 2007	Phase 1
NCT00993148	Northwestern University\|Pfizer\|Tibotec, Inc	HIV-1 Infection\|HIV Infections	May 2010	Phase 2
NCT01056874	ViiV Healthcare\|Pfizer	Healthy\|HIV Infections	March 2010	Phase 1
NCT02778204	National Institute of Allergy and Infectious Diseases (NIAID)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|ViiV Healthcare\|GlaxoSmithKline	HIV Infections	June 5, 2017	Phase 1
NCT00478231	ViiV Healthcare\|Pfizer	Acquired Immunodeficiency Syndrome\|HIV Infection	July 2007	Phase 3
NCT00525733	Rockefeller University\|Aaron Diamond AIDS Research Center\|Merck Sharp & Dohme LLC\|Pfizer	HIV Infections	October 2007	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 97.34 mM ; Need ultrasonic)

Ethanol : 6.5 mg/mL ( 12.65 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9468 mL	9.7339 mL	19.4678 mL
5 mM	0.3894 mL	1.9468 mL	3.8936 mL
10 mM	0.1947 mL	0.9734 mL	1.9468 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
4.

Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
5.

Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
6.

Add each solvent one by one: 1% DMSO >> 99% saline

Solubility: ≥ 0.5 mg/mL (0.97 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-

4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide

Maraviroc

UK 427857

Celsentri

Selzentry

4,4-Difluoro-N[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide